TABLE 1.
Effect of passive serum transfer on virus transmission
| Donor treatment | No. of infected BALB/c donors at day 4/total no. of donors (mean titer ± SEM) |
No. of infected CFW contacts/total no. of contacts (mean titer ± SEM) |
% Reduction in transmission vs B/NP-rAda | ||||
|---|---|---|---|---|---|---|---|
| Lung (log10TCID50/mL) | Nasal wash (Log10TCID50/mL) | Total (%) | Lung (log10TCID50/mL) | Nasal wash (Log10TCID50/mL) | Total (%) | ||
| A/NP+M2 serum | 11/12 (4.57 ± 0.38) | 9/12 (2.95 ± 0.12) | 12/12 (100) | 4/18 (4.41 ± 1.18) | 8/18 (3.16 ± 0.29) | 8/18 (44.4) | 20 (NS) |
| A/NP serum | 12/12 (6.32 ± 0.11) | 12/12 (3.28 ± 0.16) | 12/12 (100) | 8/18 (5.90 ± 0.36) | 8/18 (3.50 ± 0.27) | 9/18 (50.0) | 10 (NS) |
| M2 serum | 11/12 (4.68 ± 0.50) | 11/12 (3.59 ± 0.28) | 12/12 (100) | 8/18 (4.39 ± 0.53) | 10/18 (3.92 ± 0.22) | 11/18 (61.1) | 0 (NS) |
| B/NP serum | 12/12 (6.38 ± 0.10) | 11/12 (3.56 ± 0.19) | 12/12 (100) | 7/18 (5.09 ± 0.63) | 7/18 (4.05 ± 0.46) | 9/18 (50.0) | 10 (NS) |
| Naïve serum | 12/12 (6.43 ± 0.12) | 12/12 (3.32 ± 0.18) | 12/12 (100) | 7/18 (4.95 ± 0.60) | 7/18 (3.48 ± 0.38) | 8/18 (44.4) | 20 (NS) |
| A/NP+M2-rAd i.n. | 0/12 | 0/12 | 0/12 (0) | 1/18 (5.03) | 0/18 | 1/18 (5.6) | 90 (P < 0.005) |
| B/NP-rAd i.n. | 11/11 (6.73 ± 0.12) | 11/11 (4.19 ± 0.25) | 11/11 (100) | 3/18 (5.06 ± 0.56) | 10/18 (4.01 ± 0.36) | 10/18 (55.5) | |
a
NS, not significant.